In 2019, a group of international experts in women’s sexual health gathered their evidence and published a Global Consensus Position Statement on the use of testosterone therapy for women. The statement, published simultaneously in multiple major journals including the BMJ, represented the consensus of four major international societies — including the International Society for the Study of Women’s Sexual Health (ISSWSH) — and concluded, in plain language, that testosterone therapy is “recommended for postmenopausal women with hypoactive sexual desire disorder (HSDD).”
The evidence, they said, supported its use. The benefits for libido were documented. The safety profile at physiologic doses appeared acceptable.
The FDA, meanwhile, has never approved a single testosterone product specifically for use in women in the United States. Not one.
This is what a standoff looks like in clinical medicine.
What HSDD Is, and Why It Matters
Hypoactive sexual desire disorder is the clinical term for persistent, distressing low sexual desire that is not explained by a relationship problem, a psychiatric condition, another medical condition, or a medication side effect. The “distressing” qualifier is important — reduced desire by itself is not a disorder, but reduced desire that meaningfully degrades a woman’s quality of life and sense of self is a legitimate clinical complaint.
HSDD is remarkably common. Studies have consistently found that 8–16% of premenopausal women and up to 30–40% of postmenopausal women report low sexual desire with associated distress. It is, by prevalence, one of the most common sexual dysfunction complaints in clinical practice.
The biological connection to testosterone is well-established. The hypothalamus and limbic system — the brain regions central to sexual motivation — are richly supplied with androgen receptors. Testosterone at normal female physiologic concentrations modulates the activity of dopaminergic circuits that underlie desire and anticipation. When testosterone falls significantly below an individual’s functional range, those circuits function differently. The clinical result is the symptom complex described as HSDD.
This is not a novel observation. It was being published in peer-reviewed literature decades before ISSWSH wrote its consensus statement. The 2019 position paper was a consolidation of evidence that had been accumulating since at least the early 1990s.
What the Consensus Statement Actually Says
The 2019 Global Consensus Position Statement, published in The Journal of Sexual Medicine, Climacteric, the BMJ, and several other journals simultaneously, drew on a systematic review and meta-analysis of 36 controlled trials involving more than 8,000 women.
The statement’s key conclusions:
- Testosterone is the only treatment specifically shown to improve low sexual desire with associated distress in postmenopausal women.
- There is no evidence that testosterone therapy at doses targeting premenopausal physiologic concentrations increases the risk of serious adverse events, including cardiovascular events or breast cancer.
- The existing evidence supports transdermal testosterone at doses that achieve serum levels in the physiologic premenopausal range (generally targeting total testosterone of 15–50 ng/dL).
- Non-oral delivery routes (patches, gels, creams) are preferred because oral testosterone is associated with first-pass hepatic metabolism that alters lipid profiles.
The statement was careful about what it was and was not claiming: it did not endorse supraphysiologic dosing, did not recommend testosterone for premenopausal HSDD (insufficient trial data), and explicitly acknowledged that long-term safety data — particularly for cancer endpoints over 10+ years — remain limited.
That last caveat is important. It is, in fact, the core of the regulatory problem.
Why the FDA Has Not Approved a Product
The FDA’s position is not irrational, even if the consequences for patients are frustrating.
In 2004, the FDA’s Reproductive Health Drugs Advisory Committee reviewed Procter & Gamble’s application for Intrinsa, a 300 mcg/day testosterone patch for surgically menopausal women with HSDD. The committee voted 14 to 7 that the drug was effective. It voted 14 to 3 that long-term safety had not been adequately demonstrated. The agency subsequently declined to approve the application.
The specific safety concerns were:
Cardiovascular risk. Testosterone can affect lipid profiles — in general, it tends to lower HDL ("good") cholesterol to some degree — and the FDA wanted longer-duration data on actual cardiovascular events, not just surrogate markers. The Phase III Intrinsa trials ran 6 months with 12-month extensions. The FDA wanted years.
Breast cancer risk. This is the concern that carries the most emotional weight. The observational data on testosterone and breast cancer risk are genuinely complicated — some studies suggest testosterone is protective, others suggest elevated androgens in postmenopausal women are associated with increased risk, and the mechanisms through which testosterone might influence breast tissue (including its conversion to estradiol via aromatase) are not fully characterized. The FDA, in 2004, viewed the existing evidence as insufficient to rule out long-term risk in a population of postmenopausal women who might use the product for many years.
Market incentive failure. After the FDA declined Intrinsa, Procter & Gamble did not reapply. The pharmaceutical industry’s investment in female testosterone development effectively collapsed. Running a 5-year cardiovascular outcomes trial in tens of thousands of women to satisfy an uncertain regulatory pathway is a multi-hundred-million-dollar undertaking with no guarantee of approval at the end. Companies did the math and chose not to fund it. That business calculus left the clinical evidence base exactly where it was in 2004, and patients without an approved product.
The Off-Label Reality
Without an approved product, women who pursue testosterone therapy in the United States get it through two routes: off-label male products at dramatically reduced doses, or compounded preparations from specialty pharmacies.
Off-label male testosterone gels (typically 1–1.62% concentration) are prescribed at one-tenth to one-twentieth of the standard male dose. A male patient using 50 mg/day of testosterone gel might have a female patient using 2–5 mg/day of the same product. This is pharmacologically reasonable — the hormone is the hormone — but creates dosing imprecision because the male-formulated products are not calibrated for female ranges.
Compounded testosterone preparations — custom-made creams, gels, or other delivery forms from compounding pharmacies — offer flexibility in concentration and dose but lack the manufacturing standardization of FDA-approved products. Quality varies across compounding pharmacies, and absorption rates can be inconsistent. The ISSWSH consensus statement acknowledges compounded preparations as a practical reality while noting the regulatory and quality limitations.
For a product specifically designed for women’s testosterone ranges — calibrated, consistent, delivered in an appropriate concentration — there is simply nothing FDA-approved on the US market. This is the gap.
The Regulatory vs. Clinical Divide
What makes the current situation genuinely odd is that the clinical consensus and the regulatory reality have diverged substantially.
A physician who reads the 2019 ISSWSH Global Consensus Statement, reviews the supporting meta-analysis, and concludes that testosterone therapy is appropriate for their postmenopausal patient with documented HSDD is acting in alignment with the evidence. A regulatory framework that has no approved product for that indication is, in a meaningful sense, behind the evidence.
This is not unique to testosterone. The FDA approves products, not clinical practices, and the clinical evidence for a given practice can substantially outpace the regulatory environment — particularly when pharmaceutical investment in seeking approval has dried up.
The result is that women who need testosterone therapy for documented HSDD must rely on physicians who are comfortable operating off-label, pharmacies capable of compounding appropriate preparations, and patients who are willing to navigate a system that was not designed to serve them.
That is a suboptimal situation. Everyone in the relevant professional societies agrees on this. The solution — large-scale, long-term safety trials that would satisfy the FDA — requires pharmaceutical investment that is not currently arriving.
Next up: Post 4 — Dosing Women Differently: why women require doses roughly 1/10 to 1/20 of male protocols, how dose calibration works in practice, and what careful monitoring looks like.
